ArticleCureus2025
Psychosomatic and Psychological Impact of Hepatitis C: A Cross-Sectional Study of Depression, Fibrosis, and Somatic Symptoms in Treatment-Naive and Treatment-Experienced Patients Who Achieved Sustained Virologic Response.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C virus (HCV) infection is associated with neuropsychiatric symptoms, including depression and psychosomatic complaints. While direct-acting antivirals (DAAs) have revolutionized HCV treatment, their impact on mental health and systemic symptoms remains unclear. This study aimed to compare depression severity, liver fibrosis scores, and psychosomatic symptoms in treatment-naive (Tx-naive) and treatment-experienced (Tx-experienced) patients who achieved sustained virologic response (SVR). MATERIALS AND
methodsA cross-sectional observational study was conducted at two tertiary care hospitals in Pakistan. Patients with chronic HCV were categorized into Tx-naive and Tx-experienced SVR-achieved groups. Depression was assessed using the Patient Health Questionnaire-9 (PHQ-9), while fibrosis severity was determined using Fibrosis-4 (FIB-4) scores. Psychosomatic symptoms, including myalgia, asthenia, and functional dyspepsia, were documented. Statistical comparisons were performed using independent t-tests, Mann-Whitney U tests, and Chi-squared tests.
resultsA total of 142 patients were analyzed, with 69 in the Tx-naive group and 73 in the Tx-experienced SVR-achieved group. PHQ-9 scores did not significantly differ between groups (p=0.343) or FIB-4 scores (p=0.691). The prevalence of psychosomatic symptoms was comparable across both cohorts, with no statistically significant differences in individual symptoms such as asthenia, myalgia, or burning feet syndrome (all p>0.05).
conclusionsThe findings suggest that HCV itself, rather than DAA therapy, is the primary contributor to depression and somatic symptoms. Achieving SVR does not significantly alter mental health or systemic symptom burden. These results highlight the need for long-term neuropsychiatric monitoring in HCV survivors, as symptoms may persist despite viral clearance. Future research should explore the biological underpinnings of these persistent complaints and assess potential interventions for improving patient quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.